BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679
800 results:

  • 1. SUV max as Predictor of Metastatic Disease on 18 F-FDG PET-CT in Hepatocellular Carcinoma.
    Ashfaq W; Rehman K; Shahid A; Younis MN
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):394-399. PubMed ID: 38576279
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast cancer with [
    Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
    J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Lipid-Based Self-Microemulsion of Niclosamide Achieved Enhanced Oral Delivery and Anti-Tumor Efficacy in Orthotopic Patient-Derived Xenograft of Hepatocellular Carcinoma in Mice.
    Liu Y; Guerrero DQ; Lechuga-Ballesteros D; Tan M; Ahmad F; Aleiwi B; Ellsworth EL; Chen B; Chua MS; So S
    Int J Nanomedicine; 2024; 19():2639-2653. PubMed ID: 38500681
    [TBL] [Abstract] [Full Text] [Related]  

  • 4.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
    Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
    Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [
    Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
    Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
    Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
    Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
    [No Abstract]    [Full Text] [Related]  

  • 8. Co-Reactive Ligand In Situ Engineered Gold Nanoclusters with Ultra-Bright Near-Infrared Electrochemiluminescence for Ultrasensitive and Label-Free Detection of Carboxylesterase Activity.
    Guo W; Xia M; Peng D; Zhao Y; Nie Y; Zhou Y
    Anal Chem; 2024 Feb; 96(6):2369-2377. PubMed ID: 38310525
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [
    Vimalnath KV; Rajeswari A; Dixit A; Chakravarty R; Sarma HD; Kulkarni S; Jha A; Puranik A; Rangarajan V; Goswami M; Chakraborty S
    Cancer Biother Radiopharm; 2024 Feb; 39(1):82-91. PubMed ID: 38265675
    [No Abstract]    [Full Text] [Related]  

  • 10. Potential Added Value of
    Chen S; Wang G; Wu L; Chen D; Fang K; Liu W; Xu B; Zhai YQ; Li M
    BMC Gastroenterol; 2024 Jan; 24(1):37. PubMed ID: 38233765
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.
    Yang Y; Li L; Xu Y; Ouyang J; Zhou Y; Ye F; Huang Z; Zhang W; Zhou A; Zhao X; Cai J; Wang Y; Zhou J; Zhao H
    Radiol Med; 2024 Feb; 129(2):188-201. PubMed ID: 38180570
    [TBL] [Abstract] [Full Text] [Related]  

  • 12.
    Li X; Lu N; Lin L; Chen Y; Yang S; Wang H; Liu X; Wu C; Xue X; Su X; Bai X; Liang T
    J Nucl Med; 2024 Feb; 65(2):206-212. PubMed ID: 38176719
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Patlak Reconstruction Using Dynamic 18 F-FDG PET Imaging for Evaluation of Malignant liver Tumors : A Comparison of HCC, ICC, and Metastatic liver Tumors.
    Kaneko K; Nagao M; Yamamoto A; Yano K; Honda G; Tokushige K; Sakai S
    Clin Nucl Med; 2024 Feb; 49(2):116-123. PubMed ID: 38108830
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Evaluation of manual and automated approaches for segmentation and extraction of quantitative indices from [
    Krokos G; Kotwal T; Malaih A; Barrington S; Jackson P; Hicks RJ; Marsden PK; Fischer BM
    Biomed Phys Eng Express; 2024 Jan; 10(2):. PubMed ID: 38100790
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Technical Note: Impact of impurities on Yttrium-90 glass microsphere activity quantitation.
    Beattie BJ; Kirov AS; Kesner AL
    Med Phys; 2024 Mar; 51(3):2306-2310. PubMed ID: 37956259
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A prospective study of
    Shamim SA; Kumar N; Arora G; Jaswal S; Shalimar ; Gamanagatti S; Bal C
    Ann Nucl Med; 2024 Feb; 38(2):103-111. PubMed ID: 37926772
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
    AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
    Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Head-to-head comparison of
    Zhang J; Jiang S; Li M; Xue H; Zhong X; Li S; Peng H; Liang J; Liu Z; Rao S; Chen H; Cao Z; Gong Y; Chen G; Zhang R; Zhang L
    Cancer Imaging; 2023 Oct; 23(1):106. PubMed ID: 37899452
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Effect of Verapamil, a P-glycoprotein-1 and Cytochrome P450 3A4 Inhibitor, on Pharmacokinetics and Metabolic Stability of Ripretinib: A Drug-Drug Interaction Study in Rats.
    Mudavath S; Ashok D
    Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):733-746. PubMed ID: 37831396
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Explosomes: A new modality for DEB-TACE local delivery of sorafenib: In vivo proof of sustained release.
    Sakr OS; Zaitoun MMA; Amer MS; Qubisi M; Elshafeey AH; Jordan O; Borchard G
    J Control Release; 2023 Dec; 364():12-22. PubMed ID: 37816482
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 40.